PVG urges Anavex Life Sciences board ouster, CEO hire
Anavex Life Sciences faces investor pressure to replace its board and hire an experienced CEO as it shifts resources to advance blarcamesine into Phase 2b/3 for Alzheimer’s, Rett and Fragile X, and it seeks FDA guidance on pediatric Rett enrollment.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.